We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+31.99%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$150M
AUM Growth
-$13.9M
Cap. Flow
-$14M
Cap. Flow %
-9.29%
Top 10 Hldgs %
87.74%
Holding
32
New
6
Increased
8
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$12.2M
2
ARDX icon
Ardelyx
ARDX
+$10.1M
3
WGS icon
GeneDx Holdings
WGS
+$5.69M
4
BHVN icon
Biohaven
BHVN
+$4.38M
5
EYPT icon
EyePoint Inc
EYPT
+$1.49M

Sector Composition

Rank Sector Weight
1 Healthcare 81.72%
2 Consumer Discretionary 0.82%
3 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BHVN icon
1
Biohaven
BHVN
$2.07B
$44M 29.25%
804,850
+88,423
+12% +$4.38M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$20.8M 13.79%
421,583
+264,500
+168% +$12.2M
ARDX icon
3
Ardelyx
ARDX
$1.25B
$14.9M 9.89%
2,039,700
+1,175,000
+136% +$10.1M
WGS icon
4
GeneDx Holdings
WGS
$1.84B
$10.3M 6.83%
1,126,607
+948,253
+532% +$5.69M
EYPT icon
5
EyePoint Inc
EYPT
$1B
$9.55M 6.34%
461,857
+60,300
+15% +$1.49M
WBA
6
CALL
DELISTED
Walgreens Boots Alliance
WBA
$8.89M 5.91%
410,000
+310,000
+310% +$6.89M
QDEL icon
7
QuidelOrtho
QDEL
$1.14B
$7.54M 5.01%
157,201
-19,343
-11% -$1.13M
BHVN icon
8
CALL
Biohaven
BHVN
$2.07B
$6.54M 4.34%
119,500
+44,500
+59% +$2.2M
PACB icon
9
Pacific Biosciences
PACB
$432M
$5.09M 3.38%
1,356,026
-20,769
-2% -$122K
FORA
10
DELISTED
Forian
FORA
$4.5M 2.99%
1,355,807
-12,260
-0.9% -$35.6K
XBI icon
11
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$3.32M 2.21%
+35,000
New +$3.25M
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.48B
$2.72M 1.81%
535,558
SWTX
13
CALL
DELISTED
SpringWorks Therapeutics
SWTX
$2.11M 1.4%
42,900
-207,100
-83% -$9.57M
ARDX icon
14
CALL
Ardelyx
ARDX
$1.25B
$1.98M 1.31%
270,900
-1,154,100
-81% -$9.87M
STAA icon
15
CALL
STAAR Surgical
STAA
$1.13B
$1.34M 0.89%
+35,000
New +$1.14M
IMMP
16
Immutep
IMMP
$57M
$1.32M 0.87%
564,879
+48,449
+9% +$115K
CAVA icon
17
CAVA Group
CAVA
$7.57B
$1.23M 0.82%
+17,600
New +$943K
PACB icon
18
CALL
Pacific Biosciences
PACB
$432M
$938K 0.62%
250,000
-1,537,100
-86% -$9M
AGEN
19
Agenus
AGEN
$275M
$619K 0.41%
53,348
-17,500
-25% -$232K
WBA
20
DELISTED
Walgreens Boots Alliance
WBA
$596K 0.4%
+27,500
New +$611K
EYPT icon
21
CALL
EyePoint Inc
EYPT
$1B
$591K 0.39%
28,600
-191,700
-87% -$4.75M
PLTR icon
22
CALL
Palantir
PLTR
$296B
$575K 0.38%
+25,000
New +$533K
BIIB icon
23
Biogen
BIIB
$30.4B
$520K 0.35%
2,412
OPTN
24
DELISTED
OptiNose
OPTN
$475K 0.32%
+21,667
New +$481K
BDSX icon
25
Biodesix
BDSX
$218M
$43.4K 0.03%
1,518
-1,529
-50% -$52.3K

Similar funds

Oracle Investment Management's Q1 2024 Portfolio in Review

As of Q1 2024, Oracle Investment Management held 32 positions worth $150M, down 8.5% from $164M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Oracle Investment Management withdrew a net $14M in Q1 2024, closing 5 positions and reducing 10 holdings. Its most notable exit was Teladoc Health, an estimated $2.43M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 56% a quarter earlier, followed by Consumer Discretionary and Energy.

Against the trend, Oracle Investment Management opened a new position in CAVA Group worth $1.23M.

  • Oracle Investment Management's largest Q1 2024 buy was CAVA Group: 17,600 shares worth $1.23M.
  • Oracle Investment Management added most to SpringWorks Therapeutics in Q1 2024, an estimated $12.2M increase.
  • Oracle Investment Management's biggest Q1 2024 reduction was QuidelOrtho, cutting an estimated $1.13M.
  • Oracle Investment Management fully exited Teladoc Health in Q1 2024, selling an estimated $2.43M.
  • Oracle Investment Management's ten largest holdings make up 88% of its $150M portfolio in Q1 2024.
  • Oracle Investment Management opened 6 new positions and closed 5 in Q1 2024.
  • Oracle Investment Management's portfolio value fell 8.5% quarter-over-quarter to $150M.

Based on Oracle Investment Management's 13F filing for Q1 2024, filed 15 May 2024.